Recent legal battles have led to significant restrictions on compounded versions of Ozempic and Wegovy, two popular weight loss medications. A US judge has denied an injunction that would allow the continued sale of these copycat drugs, leading the FDA to halt their production. This ruling opens avenues for further regulatory actions against compounding pharmacies that have supplied these alternatives. Health experts warn that patients may resort to risky alternatives due to the loss of access to more affordable options. Concerns are growing among healthcare providers regarding the implications for patients who relied on these generic variants for obesity management.